CN102000366A - Degradable self-expandable esophageal stent and preparation method thereof - Google Patents
Degradable self-expandable esophageal stent and preparation method thereof Download PDFInfo
- Publication number
- CN102000366A CN102000366A CN2010105774195A CN201010577419A CN102000366A CN 102000366 A CN102000366 A CN 102000366A CN 2010105774195 A CN2010105774195 A CN 2010105774195A CN 201010577419 A CN201010577419 A CN 201010577419A CN 102000366 A CN102000366 A CN 102000366A
- Authority
- CN
- China
- Prior art keywords
- degradable
- esophageal stent
- self
- polymer
- filament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Materials For Medical Uses (AREA)
Abstract
The invention relates to the technical field of medical appliances, and in particular discloses a degradable self-expandable esophageal stent and a preparation method thereof. The degradable self-expandable esophageal stent is characterized in that: the degradable self-expandable esophageal stent has anticancer and developing effects and is obtained by mixing a degradable polymer and other auxiliary agents uniformly to obtain a mixture, melting and extruding the mixture by using an extruder to obtain degradable filaments, weaving the degradable filaments into a mesh esophageal stent on a mould which has a certain shape, and performing film-coating treatment on the stent. The degradable self-expandable esophageal stent not only overcomes the shortcomings of a metal stent, but also reinforces the treatment and the diagnosis of esophageal diseases by coating an anti-cancer medicament or an X-ray developing agent, so the degradable self-expandable esophageal stent has a broad application prospect.
Description
Technical field
The invention belongs to technical field of medical instruments, be specifically related to a kind of degradable self-expanding Esophageal Stent and preparation method thereof.
Background technology
Interventional therapy is to expose under the situation of focus not operating on, on blood vessel, skin, make the minim channel of several millimeters of diameters or through the original pipeline of human body, the Therapeutic Method of the wound minimum of under the guiding of image documentation equipment (angiography machine, fluoroscopic machine, CT, MR, B ultrasonic), the focus part being treated.Interventional therapy is the emerging Therapeutic Method between surgery, medical treatment, comprise in the blood vessel and getting involved and non-vascular interventional treatment, wherein Esophageal Stent belongs to non-vascular interventional treatment, it is in order to solve the repairing problem of good pernicious esophagostenosis and various esophagostoma, esophago-tracheal fistula mouth, and Esophageal Stent implantation surgery wound is little, do not need advantage such as general anesthesia and become new a selection of treatment esophagus relevant disease.
Along with the appearance of novel Esophageal Stents such as overlay film frame, antireflux support and recoverable support further improves the safety of support implantation surgery, further enlarge the range of application of Esophageal Stent, evident in efficacy.The clinical practice that the updating of Esophageal Stent material and performance makes Esophageal Stent is from the unobstructed property of simple recovery esophagus tube chamber, and bringing up to the treatment surgery can not excision or the dangerous good pernicious esophagostenosis of high operation, block and esophagel disease such as all kinds of fistula mouths of shutoff esophagus.In recent years, along with the continuous development and perfection of scope and intracavity stent technology, make that to insert Esophageal Stent under the scope easy to learn, easy to operate, effective.
At present, the domestic medical catheter that is used for the esophagostenosis interventional therapy of China substantially all is the Ultimum Ti metal catheter support after establishment, and it can prevent effectively that organ is inaccessible or narrow.But the application of metal rack also comes with some shortcomings, as the metal rack that forever the retains reaction that causes inflammation easily, metal rack can discharge the toxic metals ion, as metals such as Ni, in addition, whether support can still require study in fatigue fracture, in case and the support accidental just can only adopt the method for operation to take out, bring extra misery to patient.These have all limited the application of metal rack in the esophagus interventional therapy.
Along with the development of Biodegradable material, brought revolutionary variation for intervention support and interventional therapy.Biodegradable material is a kind of organic compound of synthetic, in vivo can be through approach such as hydrolysis, enzymolysis, be degraded into low molecular weight compound or monomer gradually, thereby be excreted or participate in the body homergy, its benefit is its biologically inert and vivo degradation, has been widely used in various aspects such as drug release carrier, operation suture thread, surgical operation and tissue renovation material at present.Further investigation along with Biodegradable polymer material, the homopolymer and the random copolymer of aliphatic cyclic ester (CL, LA, GA, EO) are the absorbable biological medicinal material that is most widely used in the world, and pass through the permission of the United States Federal's health and food control office (FDA), so the aliphatic cyclic ester can be used as the material of preparation degradable catheter holder in interventional therapy.Degradation material is made filament by melt extruding method according to the specific dimensions requirement, utilize the degradable filament can weave webbed degradable Esophageal Stent then.After the degradable Esophageal Stent is inserted human body, can after being set in certain hour, degrade, being converted into harmless micromolecule gets rid of external, even the support accidental takes place, also can be by disappearing after the human body degraded and absorbed, need not operation and take out, thereby this support has the incomparable advantage of metal Esophageal Stent.
Summary of the invention
The object of the present invention is to provide a kind of degradable self-expanding Esophageal Stent and preparation method thereof, solve the problems of used metal rack in the present esophagus interventional therapy, and strengthened the treatment and the diagnosis of esophagel disease by coated medicament and/or X-ray developing agent.
In order to solve these problems of the prior art, technical scheme provided by the invention is:
A kind of degradable self-expanding Esophageal Stent, it is characterized in that described support is the netted Esophageal Stent with definite shape of being worked out by the degradable polymer filament, filament is made up of the auxiliary agent of degradable polymer and certain content, the filament surfaces of forming support is covered with the degradable polymer film that contains medicine and/or X-ray developing agent, and described degradable Esophageal Stent has the self-expanding function.
Preferably, described degradable polymer is selected from the copolymer or the blend of one or several polymer in the degradable polymer materials such as polylactic acid, polycaprolactone, polyglycolic acid, Polyethylene Glycol, polylcaprolactone, polyhydroxybutyrate valerate, Polyethylene Glycol, degradable polyurethane, and the molecular weight control of polymer is 0.1～800,000.
Preferably, described auxiliary agent is selected from one or more in nucleator, plasticizer, the flexibilizer etc.
Preferably, described medicine is selected from one or more in the medicine that paclitaxel, amycin, ibuprofen, daunorubicin, mitoxantrone etc. have treatment esophageal carcinoma function.
Preferably, the diameter of described degradable filament is 0.1～3mm.
Preferably, the diameter of described netted Esophageal Stent is 15～50mm, and length is 30～200mm.
The present invention also provides a kind of method for preparing degradable self-expanding Esophageal Stent, it is characterized in that said method comprising the steps of:
(1) raw material mix stages: the degradable polymer of getting gross mass 60～98%, the auxiliary agent that adds gross mass 1～30% after drying mixes raw material promptly getting mixed material in mixer under 25～80 ℃ of temperature and 100～1000 rev/mins of speed conditions;
(2) filament preparatory phase: at 100～200 ℃ of extrusion temperatures, 10～100 rev/mins of screw speeds, the mixed material that under 1.0～20.0kg/h rate of feeding and the 0.1～20m/s hauling speed condition step (1) is obtained melt extrude by extruder and make the degradable filament;
(3) the support establishment stage: on the mould of definite shape, be compiled into netted Esophageal Stent with the degradable filament;
(4) the support overlay film stage: add solvent the degradable polymer of gross mass 0.1～40% and the cancer therapy drug and/or the X-ray developing agent of gross mass 0.1～10% are made into 0.01～0.2g/ml solution, network is immersed a period of time in the solution, take out network then and solvent is volatilized fast and do, handle promptly obtaining degradable self-expanding Esophageal Stent at last with the ethane peroxide suffocating sterilization.
Preferably, described degradable polymer is selected from the copolymer or the blend of one or several polymer in the degradable polymer materials such as polylactic acid, polycaprolactone, polyglycolic acid, polylcaprolactone, polyhydroxybutyrate valerate, Polyethylene Glycol, degradable polyurethane, and the molecular weight control of polymer is 0.1～800,000; Described auxiliary agent is selected from one or more in nucleator, plasticizer, the flexibilizer etc.; Described medicine is selected from one or more in the medicine that paclitaxel, amycin, ibuprofen, daunorubicin, mitoxantrone etc. have treatment esophageal carcinoma function; Described solvent is selected from dichloromethane, chloroform, acetone, methanol, ethanol, oxolane, dioxane, N, dinethylformamide, N, in the volatile solvents such as N-diethylformamide, N,N-dimethylacetamide or dimethyl sulfoxide one or more; The diameter of described degradable filament is 0.1～3mm; The diameter of described netted Esophageal Stent is 15～50mm, and length is 30～200mm.
The degradable filament that makes by extruder in the technical solution of the present invention is compiled into the netted Esophageal Stent of different shape, and this support is carried out overlay film handle the degradable self-expanding Esophageal Stent that obtains having anticancer and/or development effect, this invention has not only overcome the deficiency of metal rack, and strengthen the treatment and the diagnosis of esophagel disease by applying cancer therapy drug and/or X-ray developing agent, have broad application prospects.
With respect to scheme of the prior art, advantage of the present invention is:
1, in the technical solution of the present invention except that medicine and X-ray developing agent, raw material is Biodegradable material, compares with metal rack with plastic stent, has the favorable tissue compatibility, the reaction that is difficult for causing inflammation does not cause phenomenons such as poisoning, haemolysis blood coagulation and allergy;
2, can degrade voluntarily after the mechanical support effect of the organ tube wall being finished certain hour, catabolite has no side effect to tissue, need not second operation and takes out conduit;
3, add the degradable polymer auxiliary agent, can obviously improve toughness, plasticity and the processing characteristics of degradation material;
4, on netted Esophageal Stent, apply treatment and the diagnosis that cancer therapy drug or X-ray developing agent are strengthened esophagel disease, effectively solve various esophagel diseases.
The specific embodiment
Below in conjunction with specific embodiment such scheme is described further.Should be understood that these embodiment are used to the present invention is described and are not limited to limit the scope of the invention.The implementation condition that adopts among the embodiment can be done further adjustment according to the condition of concrete producer, and not marked implementation condition is generally the condition in the normal experiment.
The preparation of embodiment 1 degradable self-expanding Esophageal Stent
Get the polylactic acid (molecular weight is 250,000) of gross mass 80%, add the nucleator of gross mass 1% after drying, under 40 ℃ of temperature and 300 rev/mins of speed conditions, raw material mixed promptly getting mixed material in mixer; At 160 ℃ of extrusion temperatures, 30 rev/mins of screw speeds, 2.0kg/h under rate of feeding and the 1m/s hauling speed condition mixed material melt extruded by extruder and obtains the degradable filament that diameter is 0.3mm, on the mould of definite shape, be compiled into netted Esophageal Stent with the degradable filament, support external diameter 30mm, long 100mm; The adding dichloromethane is made into 0.10g/ml solution with the polylactic acid (molecular weight is 150,000) and the paclitaxel of gross mass 9% of gross mass 10%, to have network immerses in the solution, after taking out network the quick volatilization of dichloromethane is done, handled promptly obtaining degradable self-expanding Esophageal Stent at last with the ethane peroxide suffocating sterilization.
The preparation of embodiment 2 degradable self-expanding Esophageal Stents
Get the polylactic acid (molecular weight is 250,000) of gross mass 50% and the polycaprolactone (molecular weight is 70,000) of gross mass 30%, the nucleator that adds gross mass 1% after drying mixes raw material promptly getting mixed material in mixer under 40 ℃ of temperature and 300 rev/mins of speed conditions; At 160 ℃ of extrusion temperatures, 30 rev/mins of screw speeds, 2.0kg/h under rate of feeding and the 1m/s hauling speed condition mixed material melt extruded by extruder and obtains the degradable filament that diameter is 0.3mm, on the mould of definite shape, be compiled into netted Esophageal Stent with the degradable filament, support external diameter 25mm, long 80mm; The adding dichloromethane is made into 0.10g/ml solution with the polylactic acid (molecular weight is 150,000) and the X-ray developing agent of gross mass 9% of gross mass 10%, to have network immerses in the solution, after taking out network the quick volatilization of dichloromethane is done, handled promptly obtaining degradable self-expanding Esophageal Stent at last with the ethane peroxide suffocating sterilization.
The preparation of embodiment 3 degradable self-expanding Esophageal Stents
Get the polylactic acid (molecular weight is 250,000) of gross mass 50% and the polycaprolactone (molecular weight is 70,000) of gross mass 21%, the plasticizer that adds gross mass 10% after drying mixes raw material promptly getting mixed material in mixer under 40 ℃ of temperature and 300 rev/mins of speed conditions; At 170 ℃ of extrusion temperatures, 35 rev/mins of screw speeds, 3.0kg/h under rate of feeding and the 0.5m/s hauling speed condition mixed material melt extruded by extruder and obtains the degradable filament that diameter is 0.8mm, on the mould of definite shape, be compiled into netted Esophageal Stent with the degradable filament, support external diameter 35mm, long 120mm; The adding chloroform is made into 0.10g/ml solution with the degradable polyurethane (molecular weight is 80,000) and the paclitaxel of gross mass 9% of gross mass 10%, to have network immerses in the solution, after taking out network the quick volatilization of chloroform is done, handled promptly obtaining degradable self-expanding Esophageal Stent at last with the ethane peroxide suffocating sterilization.
The preparation of embodiment 4 degradable self-expanding Esophageal Stents
Get the polylactic acid (molecular weight is 200,000) of gross mass 50% and the polycaprolactone (molecular weight is 70,000) of gross mass 25%, add the plasticizer of gross mass 5% and the nucleator of gross mass 1% after drying, under 40 ℃ of temperature and 300 rev/mins of speed conditions, raw material mixed promptly getting mixed material in mixer; At 160 ℃ of extrusion temperatures, 30 rev/mins of screw speeds, 2.0kg/h under rate of feeding and the 1m/s hauling speed condition mixed material melt extruded by extruder and obtains the degradable filament that diameter is 0.3mm, on the mould of definite shape, be compiled into netted Esophageal Stent with the degradable filament, support external diameter 40mm, long 150mm; The adding chloroform is made into 0.10g/ml solution with the polylactic acid-glycolic guanidine-acetic acid copolymer (molecular weight is 150,000) and the X-ray developing agent of gross mass 9% of gross mass 10%, to have network immerses in the solution, after taking out network the quick volatilization of chloroform is done, handled promptly obtaining degradable self-expanding Esophageal Stent at last with the ethane peroxide suffocating sterilization.
The preparation of embodiment 5 degradable self-expanding Esophageal Stents
Get the polylactic acid (molecular weight is 200,000) of gross mass 50% and the polycaprolactone (molecular weight is 70,000) of gross mass 20%, add the plasticizer of gross mass 10% and the nucleator of gross mass 1% after drying, under 40 ℃ of temperature and 300 rev/mins of speed conditions, raw material mixed promptly getting mixed material in mixer; 170 ℃ of extrusion temperatures, 35 rev/mins of screw speeds, 3.0kg/h under rate of feeding and the 0.5m/s hauling speed condition mixed material melt extruded by extruder and obtains the degradable filament that diameter is 0.8mm, on the mould of definite shape, be compiled into netted Esophageal Stent with the degradable filament, support external diameter 45mm, long 200mm; The adding chloroform is made into 0.10g/ml solution with polylactic acid-glycolic guanidine-acetic acid copolymer (molecular weight is 150,000) and the paclitaxel of gross mass 3%, the amycin of gross mass 3%, the X-ray developing agent of gross mass 3% of gross mass 10%, to have network immerses in the solution, after taking out network the quick volatilization of chloroform is done, handled promptly obtaining degradable self-expanding Esophageal Stent at last with the ethane peroxide suffocating sterilization.
Above-mentioned example only is explanation technical conceive of the present invention and characteristics, and its purpose is to allow the people who is familiar with this technology can understand content of the present invention and enforcement according to this, can not limit protection scope of the present invention with this.All equivalent transformations that spirit is done according to the present invention or modification all should be encompassed within protection scope of the present invention.
Claims (8)
1. degradable self-expanding Esophageal Stent, it is characterized in that described support is the netted Esophageal Stent with definite shape of being worked out by the degradable polymer filament, filament is made up of the auxiliary agent of degradable polymer and certain content, the filament surfaces of forming support is covered with the degradable polymer film that contains medicine and/or X-ray developing agent, and described degradable Esophageal Stent has the self-expanding function.
2. degradable self-expanding Esophageal Stent according to claim 1, it is characterized in that described degradable polymer is selected from the copolymer or the blend of one or several polymer in the degradable polymer materials such as polylactic acid, polycaprolactone, polyglycolic acid, polylcaprolactone, polyhydroxybutyrate valerate, Polyethylene Glycol, degradable polyurethane, the molecular weight control of polymer is 0.1～800,000.
3. degradable self-expanding Esophageal Stent according to claim 1 is characterized in that described auxiliary agent is selected from one or more in nucleator, plasticizer, the flexibilizer etc.
4. degradable self-expanding Esophageal Stent according to claim 1 is characterized in that described medicine is selected from one or more in the medicine that paclitaxel, amycin, ibuprofen, daunorubicin, mitoxantrone etc. have treatment esophageal carcinoma function.
5. degradable self-expanding Esophageal Stent according to claim 1, the diameter that it is characterized in that described degradable filament is 0.1～3mm.
6. degradable self-expanding Esophageal Stent according to claim 1, the diameter that it is characterized in that described netted Esophageal Stent is 15～50mm, length is 30～200mm.
7. method for preparing degradable self-expanding Esophageal Stent is characterized in that described preparation method may further comprise the steps:
(1) raw material mix stages: the degradable polymer of getting gross mass 60～98%, the auxiliary agent that adds gross mass 1～30% after drying mixes raw material promptly getting mixed material in mixer under 25～80 ℃ of temperature and 100～1000 rev/mins of speed conditions;
(2) filament preparatory phase: at 100～200 ℃ of extrusion temperatures, 10～100 rev/mins of screw speeds, the mixed material that under 1.0～20.0kg/h rate of feeding and the 0.1～20m/s hauling speed condition step (1) is obtained melt extrude by extruder and make the degradable filament;
(3) the support establishment stage: on the mould of definite shape, be compiled into netted Esophageal Stent with the degradable filament;
(4) the support overlay film stage: add solvent the degradable polymer of gross mass 0.1～40% and the cancer therapy drug and/or the X-ray developing agent of gross mass 0.1～10% are made into 0.01～0.2g/ml solution, network is immersed a period of time in the solution, take out network then and solvent is volatilized fast and do, handle promptly obtaining degradable self-expanding Esophageal Stent at last with the ethane peroxide suffocating sterilization.
8. method according to claim 7, it is characterized in that described degradable polymer is selected from the copolymer or the blend of one or several polymer in the degradable polymer materials such as polylactic acid, polycaprolactone, polyglycolic acid, polylcaprolactone, polyhydroxybutyrate valerate, Polyethylene Glycol, degradable polyurethane, the molecular weight control of polymer is 0.1～800,000; Described auxiliary agent is selected from one or more in nucleator, plasticizer, the flexibilizer etc.; Described medicine is selected from one or more in the medicine that paclitaxel, amycin, ibuprofen, daunorubicin, mitoxantrone etc. have treatment esophageal carcinoma function; Described solvent is selected from dichloromethane, chloroform, acetone, methanol, ethanol, oxolane, dioxane, N, dinethylformamide, N, in the volatile solvents such as N-diethylformamide, N,N-dimethylacetamide or dimethyl sulfoxide one or more; The diameter of described degradable filament is 0.1～3mm; The diameter of described netted Esophageal Stent is 15～50mm, and length is 30～200mm.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010105774195A CN102000366A (en) | 2010-12-08 | 2010-12-08 | Degradable self-expandable esophageal stent and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010105774195A CN102000366A (en) | 2010-12-08 | 2010-12-08 | Degradable self-expandable esophageal stent and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102000366A true CN102000366A (en) | 2011-04-06 |
Family
ID=43808232
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010105774195A Pending CN102000366A (en) | 2010-12-08 | 2010-12-08 | Degradable self-expandable esophageal stent and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102000366A (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102295736A (en) * | 2011-06-03 | 2011-12-28 | 大连理工大学 | Preparation method of polylactic acid material with X-ray developing functions |
| CN104382671A (en) * | 2014-09-11 | 2015-03-04 | 南京微创医学科技有限公司 | Degradable human body stent capable of effectively preventing transposition and reducing hyperplasia and manufacturing method |
| CN105802197A (en) * | 2016-04-06 | 2016-07-27 | 同济大学 | Preparation method of degradable biological membrane |
| CN111655303A (en) * | 2018-01-08 | 2020-09-11 | 铸造疗法股份有限公司 | Devices, systems and methods for treating intraluminal cancer via controlled delivery of therapeutic agents |
| US11964076B2 (en) | 2015-03-31 | 2024-04-23 | Foundry Therapeutics, Inc. | Multi-layered polymer film for sustained release of agents |
| US11969500B2 (en) | 2017-10-06 | 2024-04-30 | Foundry Therapeutics, Inc. | Implantable depots for the controlled release of therapeutic agents |
| CN118022071A (en) * | 2024-01-31 | 2024-05-14 | 徐州秀微医疗科技有限公司 | Developing mark for micro-guide wire and preparation method thereof |
| US12303619B2 (en) | 2018-08-28 | 2025-05-20 | Foundry Therapeutics, Inc. | Polymer implants |
| US12458589B2 (en) | 2018-05-12 | 2025-11-04 | Foundry Therapeutics, Inc. | Implantable polymer depots for the controlled release of therapeutic agents |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101513367A (en) * | 2009-04-02 | 2009-08-26 | 中国人民解放军总医院第二附属医院 | Degradable esophagus tubular intervention support and preparation method thereof |
| CN101631518A (en) * | 2006-10-25 | 2010-01-20 | 生物传感器国际集团有限公司 | Temporary intraluminal stent and methods of making and using same |
-
2010
- 2010-12-08 CN CN2010105774195A patent/CN102000366A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101631518A (en) * | 2006-10-25 | 2010-01-20 | 生物传感器国际集团有限公司 | Temporary intraluminal stent and methods of making and using same |
| CN101513367A (en) * | 2009-04-02 | 2009-08-26 | 中国人民解放军总医院第二附属医院 | Degradable esophagus tubular intervention support and preparation method thereof |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102295736A (en) * | 2011-06-03 | 2011-12-28 | 大连理工大学 | Preparation method of polylactic acid material with X-ray developing functions |
| CN104382671A (en) * | 2014-09-11 | 2015-03-04 | 南京微创医学科技有限公司 | Degradable human body stent capable of effectively preventing transposition and reducing hyperplasia and manufacturing method |
| US12290616B2 (en) | 2015-03-31 | 2025-05-06 | Foundry Therapeutics, Inc. | Multi-layered polymer film for sustained release of agents |
| US11964076B2 (en) | 2015-03-31 | 2024-04-23 | Foundry Therapeutics, Inc. | Multi-layered polymer film for sustained release of agents |
| CN105802197A (en) * | 2016-04-06 | 2016-07-27 | 同济大学 | Preparation method of degradable biological membrane |
| US11969500B2 (en) | 2017-10-06 | 2024-04-30 | Foundry Therapeutics, Inc. | Implantable depots for the controlled release of therapeutic agents |
| US12290595B2 (en) | 2017-10-06 | 2025-05-06 | Foundry Therapeutics, Inc. | Implantable depots for the controlled release of therapeutic agents |
| CN111655303A (en) * | 2018-01-08 | 2020-09-11 | 铸造疗法股份有限公司 | Devices, systems and methods for treating intraluminal cancer via controlled delivery of therapeutic agents |
| US12364792B2 (en) | 2018-01-08 | 2025-07-22 | Foundry Therapeutics, Inc. | Devices, systems, and methods for treating intraluminal cancer via controlled delivery of therapeutic agents |
| US12458589B2 (en) | 2018-05-12 | 2025-11-04 | Foundry Therapeutics, Inc. | Implantable polymer depots for the controlled release of therapeutic agents |
| US12303619B2 (en) | 2018-08-28 | 2025-05-20 | Foundry Therapeutics, Inc. | Polymer implants |
| CN118022071B (en) * | 2024-01-31 | 2024-09-20 | 徐州秀微医疗科技有限公司 | Developing mark for micro-guide wire and preparation method thereof |
| CN118022071A (en) * | 2024-01-31 | 2024-05-14 | 徐州秀微医疗科技有限公司 | Developing mark for micro-guide wire and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102000366A (en) | Degradable self-expandable esophageal stent and preparation method thereof | |
| CN102048602B (en) | Preparation method of meshy degradable blood vessel stent | |
| CN102000365A (en) | Degradable bile duct bracket with stone dissolution function and preparation method thereof | |
| Ueda et al. | Polyhydroxyalkanonate derivatives in current clinical applications and trials | |
| CN101513367B (en) | Degradable esophagus tubular intervention support and preparation method thereof | |
| CN103239265B (en) | Anastomat for gastrointestinal tract anastomosis surgery and production method thereof | |
| WO2019076178A1 (en) | Degradation time controllable and breaking elongation adjustable medical degradable polyurethane | |
| CN109503797A (en) | A kind of medical degradable polyurethane and application thereof with antibacterial activity | |
| CN103961193A (en) | Self-expanding devices and methods therefor | |
| DE69836439D1 (en) | POLYHYDROXYALKANOATE COMPOSITIONS WITH CONTROLLED DISMANTLING SPEEDS | |
| EP2937106A1 (en) | Biodegradable polyester frame and preparation method therefor | |
| CN103374208B (en) | A kind of can the polymer materials and preparation method thereof of gradient degradation | |
| JP2012520297A (en) | Products and methods for the treatment of vascular diseases | |
| CN101768345A (en) | Polylactic acid degradable film | |
| TWI612977B (en) | Bioabsorbable fibers and implants containing drugs | |
| CN102008758A (en) | Degradable bile duct support and preparation method thereof | |
| CN102284088A (en) | Absorbable vascular stent | |
| CN101947353B (en) | Degradable medical composite conduit containing functional nano coating and preparation method thereof | |
| CN102028569A (en) | Degradable bracket with radiotherapy and chemotherapy synergistic effect and preparation method thereof | |
| CN102078229A (en) | Degradable coronary artery scaffold and preparation method thereof | |
| CN103110985A (en) | Biodegradable bracket with multiple drugs | |
| CN101069660B (en) | A preparation method of biliary stent carrying drugs | |
| CN105797218B (en) | Coating composition and medical instrument | |
| CN101999952A (en) | Polycaprolactone (PCL) and polylactic acid (PLA) human body absorbable vascular stent and preparation method thereof | |
| JPH01503204A (en) | Implant device with hydrophobic component |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| DD01 | Delivery of document by public notice |
Addressee: Suzhou Tongke Biological Material Co., Ltd. Document name: the First Notification of an Office Action |
|
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20110406 |